168P Sacituzumab govitecan (SG) efficacy in patients with metastatic triple-negative breast cancer (mTNBC) by HER2 immunohistochemistry (IHC) status: Findings from the phase III ASCENT study
SA Hurvitz, Amit Bardia, Kevin Punie, Kevin Kalinsky, Javier Cortés, Joyce O’Shaughnessy, L.A. Carey, H. S. Rugo, Oh Kyu Yoon, Yuting Pan, Rosemary Delaney, Scott Hofsess, P. Hodgkins, S-C. Phan, Véronique Dièras
Topics & Concepts
MedicineInternal medicineOncologyPopulationVinorelbineMetastatic breast cancerGemcitabineClinical endpointBreast cancerProgression-free survivalPhases of clinical researchTriple-negative breast cancerGastroenterologyCancerChemotherapyRandomized controlled trialEnvironmental healthCisplatinHER2/EGFR in Cancer ResearchCancer Treatment and PharmacologyAdvanced Breast Cancer Therapies